Posted Nov. 28, 2012 at 5:24 a.m.
Duke links genetics to hepatitis C treatment effectiveness
Image 1 of 3 · Next Image…
Research Triangle Park, N.C. — GlaxoSmithKline and Boehringer Ingelheim GmbH are among drugmakers delaying introductions or partially withdrawing their products in some European markets as governments raise the bar on what they're willing to pay.
GSK, others rebel against European government drug cuts
Post a comment
Print this blog postE-mail blog post
Share
Duke links genetics to hepatitis C treatment effectiveness
Image 1 of 3 · Next Image…
Research Triangle Park, N.C. — GlaxoSmithKline and Boehringer Ingelheim GmbH are among drugmakers delaying introductions or partially withdrawing their products in some European markets as governments raise the bar on what they're willing to pay.
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 Bloomberg. All rights reserved.Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows